Kevin P. Foley - Concepedia

Author

Kevin P. Foley

Also Known As

Blatch, Gregory L., Foley, Kevin, K Foley, K P Foley, K. Foley, K. P. Foley, K.P. FOLEY, K.P. Foley, KEVIN FOLEY, KEVIN P. FOLEY

201

Publications

8.8K

Citations

H-Index

148

Concepts

All Affiliations

McMaster University Population Health Research Institute Synta Pharmaceuticals (United States)Hospital for Sick Children GlaxoSmithKline (United States)

About

Kevin P. Foley is an author at McMaster University specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	32	4.7K
2	Health Sciences	10	10	475
3	Public Health	4	4	98
4	Natural Sciences	3	3	128
5	Nursing	1	1	24

Kevin P. Foley

Publications

6.5K

Citations

H-Index

Page 1

	Year	Citations
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease Jane A. Gross, Janet Johnston, Sherri Mudri, Nature Autoimmune DiseaseAutoantibody ProductionHumoral ResponseImmune RegulationImmunology	2000	1.2K
Design of amidobenzimidazole STING receptor agonists with systemic activity Joshi M. Ramanjulu, G. Scott Pesiridis, Jingsong Yang, Nature Systemic ActivityMedicineMechanism Of ActionPharmacological AgentPharmacotherapy	2018	803
TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease Jane A. Gross, Stacey R. Dillon, Sherri Mudri, Immunity ImmunogeneticsSignal TransductionAutoimmune DiseaseImmune Cell DevelopmentImmunology	2001	620
Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4 Joseph F. Cavallari, Morgan D. Fullerton, Brittany M. Duggan, Cell Metabolism Metabolic SyndromeBiochemistryMedicineMetabolic RegulationMetabolism	2017	237
Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy Weiwen Ying, Zhenjian Du, Lijun Sun, Molecular Cancer Therapeutics Cancer TherapyGanetespib Exhibits PotentPharmacotherapyTumor BiologySystems Pharmacology	2011	227
Defective <scp>NOD</scp> 2 peptidoglycan sensing promotes diet‐induced inflammation, dysbiosis, and insulin resistance Emmanuel Denou, Karine Lolmède, Lucile Garidou, EMBO Molecular Medicine	2015	185
Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes Carlos D. Rosé, Steven Pans, Ingele Casteels, Lara D. Veeken	2014	173
Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer Takeshi Shimamura, Samanthi A. Perera, Kevin P. Foley, Clinical Cancer Research	2012	165
Fluvastatin Causes NLRP3 Inflammasome-Mediated Adipose Insulin Resistance Brandyn D. Henriksbo, Trevor C. Lau, Joseph F. Cavallari, Diabetes	2014	138
Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation Kevin P. Foley The EMBO Journal Myc Antagonist Mad1Cell Cycle ExitCell DivisionGranulocyteHematology	1998	136

Page 1